{"nctId":"NCT01721954","briefTitle":"FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer","startDateStruct":{"date":"2013-05-01","type":"ACTUAL"},"conditions":["Colorectal Cancer Metastatic"],"count":209,"armGroups":[{"label":"Control Arm","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: FOLFOX6m"]},{"label":"Experimental Arm","type":"EXPERIMENTAL","interventionNames":["Drug: FOLFOX6m","Device: SIR-Spheres microspheres"]}],"interventions":[{"name":"FOLFOX6m","otherNames":[]},{"name":"SIR-Spheres microspheres","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent\n* Unequivocal and measurable CT evidence of liver metastases which are not treatable by surgical resection or local ablation\n* Limited extra-hepatic metastases in the lung and/or lymph nodes are permitted (Lung: 5 lesions total, \\< 1 cm, or 1 single lesion of up to 1.7 cm; Lymph nodules in one single anatomic area (pelvis, abdomen or chest): any number, \\< 2 cm)\n* All imaging evidence used as part of the screening process must be within 28 days\n* Suitable for either treatment regimen\n* WHO performance status 0-1\n* Adequate hematological, renal and hepatic function\n* Life expectancy of at least 3 months without any active treatment\n\nExclusion Criteria:\n\n* Evidence of ascites, cirrhosis, portal hypertension, main portal or venous involvement or thrombosis as determined by clinical or radiologic assessment\n* Previous radiotherapy delivered to the liver\n* Non-malignant disease that would render the patient unsuitable for treatment according to the protocol\n* Peripheral neuropathy \\> grade 2 (NCI-CTC)\n* Dose-limiting toxicity associated with previous adjuvant 5-FU or oxaliplatin chemotherapy\n* Prior non-adjuvant chemotherapy for any malignancy. Adjuvant chemotherapy for colorectal cancer is permitted provided that it was completed more than 6 months before entry into the study\n* Pregnant or breast feeding\n* Concurrent or prior history of cancer other than adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix\n* Allergy to contrast media that would preclude angiography of the hepatic arteries","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"OS defined as the time interval between the date of randomization and the date of death from any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.9","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival","description":"PFS defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as an increase in the sum of the longest diameters of ≥ 20% and an absolute increase in the sum of the longest diameters of ≥ 5 mm, or the appearance of a new lesion.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"11.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":47,"n":92},"commonTop":["Neuropathy peripheral","Nausea","Fatigue","Diarrhoea","Neutropenia"]}}}